ODG
ESPR

O'Dell Group’s Esperion Therapeutics ESPR Stock Holding History

O'Dell Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,500
Closed -$13.5K – 201
2023
Q4 		$13.5K Buy
+4,500
New +$5.84K ﹤0.01% 324
2023
Q3 		– Sell
-4,500
Closed -$6.25K – 185
2023
Q2 		$6.25K Buy
+4,500
New +$6.28K ﹤0.01% 377
2022
Q3 		– Sell
-261
Closed -$2K – 431
2022
Q2 		$2K Hold
261
– – ﹤0.01% 403
2022
Q1 		$1K Buy
+261
New +$1.12K ﹤0.01% 476

Other funds holding ESPR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return